2026/9/21 14:09:45
A Phase 1b/2a Study of Legubicin in Patients with Pretreated NSCLC Selected for WCLC 2026 Poster Tour
Company Overview
Affinity (Shanghai) Biopharmaceutical Co., Ltd. (“Affinity”) was founded in Zhangjiang, Shanghai in 2012. Dedicated to addressing the toxicity challenges of conventional chemotherapy and targeted therapies and focusing on unmet clinical needs in oncology, we are a China-founded, globally focused biopharmaceutical enterprise independently developing first-in-class anti-cancer therapeutics.
With its proprietary TMEA technology platform, Affinity strategically focuses on two breakthrough therapeutic modalities: XDC and IO. The company is committed to delivering transformative oncology therapies with reduced toxicity, enhanced efficacy, and inherent potential for synergistic combination use.
Partnerships
Affinity aims to become a fully integrated, innovative biopharmaceutical company, and establishing broad partnerships is a core pillar of our strategy.
News
Affinity (Shanghai) Biopharmaceutical Co., Ltd.
Email: admin@affinity.net.cn
R&D and Business Development Cooperation: bd@affinity.net.cn
PR ：pr@affinity.net.cn
Address: 3rd Floor, Building 1, No. 368 Zhangjiang Road, Pudong New Area, Shanghai, China